[의약뉴스] Hanmi Pharm announced on the 12th that CEO Kwon Se-chang, who has played a pivotal role in Hanmi’s R&D sector for the past 20 years, will step down due to his decision to promote new R&D innovations in 2023, which marks the 50th anniversary of the its foundation.
Kwon, who joined Hanmi Pharm as a research scientist in 1996, has served as the head of research center and general manager of R&D, leading many of Hanmi Pharm’s new biological drug projects and playing a key in the development of Hanmi’s proprietary technology platform “Lapscovery”.
Rolontis, a new biologic developed under Kwon’s direction, received US FDA approval for the first time as a new cancer biologic developed by a Korean pharmaceutical company.
Meanwhile, Vice President Lee Gwan-soon, who led the research and development of Hanmi Pharm together with President Kwon, stepped down as vice president on the 12th and was appointed adviser. Consultant Lee also plans to serve faithfully as president of the Lim Sung-ki Foundation, advising on R&D activities between Korea and the United States.
Advisor Lee Gwan-soon, who joined Hanmi Pharmaceutical in 1984 as a research scientist, was the youngest research director in the domestic pharmaceutical industry and served as CEO and vice president of Hanmi Pharmaceutical.
A Hanmi Pharm official said, “2023 is a significant year to celebrate the 50th anniversary of the founding of Hanmi Pharm Group. I have decided to step down,” he said.
Copyright © Medicine News Unauthorized reproduction and redistribution prohibited
